ABSTRACT
The development of intestinal organoid technology has greatly accelerated research in the field of colorectal cancer. Contrary to traditional cancer cell lines, organoids are composed of multiple cell types arranged in 3D structures highly reminiscent of their native tissues. Thus, organoids provide a near-physiological and readily accessible model to study tissue morphogenesis, adult stem cell behavior and tumorigenesis. Here, we provide protocols for establishing intestinal organoid cultures from genetically modified mouse lines and describe methods to overexpress and knockout genes of interest using lentiviral-based approaches.
Subject(s)
Cell Transformation, Neoplastic/pathology , Colorectal Neoplasms/pathology , Organoids/pathology , Signal Transduction , Tissue Culture Techniques/methods , Adenomatous Polyposis Coli Protein/genetics , Animals , Colon/pathology , Colorectal Neoplasms/genetics , Gene Knockout Techniques/instrumentation , Gene Knockout Techniques/methods , Genetic Vectors/genetics , Lentivirus/genetics , Mice , Mice, Transgenic , Neoplasms, Experimental/genetics , Neoplasms, Experimental/pathology , Rectum/pathology , Tissue Culture Techniques/instrumentationABSTRACT
Precise control of gene expression during development is orchestrated by transcription factors and co-regulators including chromatin modifiers. How particular chromatin-modifying enzymes affect specific developmental processes is not well defined. Here, we report that GCN5, a histone acetyltransferase essential for embryonic development, is required for proper expression of multiple genes encoding components of the fibroblast growth factor (FGF) signaling pathway in early embryoid bodies (EBs). Gcn5-/- EBs display deficient activation of ERK and p38, mislocalization of cytoskeletal components, and compromised capacity to differentiate toward mesodermal lineage. Genomic analyses identified seven genes as putative direct targets of GCN5 during early differentiation, four of which are cMYC targets. These findings established a link between GCN5 and the FGF signaling pathway and highlighted specific GCN5-MYC partnerships in gene regulation during early differentiation.
Subject(s)
Cell Differentiation , Embryoid Bodies/metabolism , Fibroblast Growth Factors/metabolism , MAP Kinase Signaling System , Proto-Oncogene Proteins c-myc/metabolism , p300-CBP Transcription Factors/metabolism , Animals , Embryoid Bodies/cytology , Fibroblast Growth Factors/genetics , Mice , Mice, Knockout , Proto-Oncogene Proteins c-myc/genetics , p300-CBP Transcription Factors/genetics , p38 Mitogen-Activated Protein Kinases/genetics , p38 Mitogen-Activated Protein Kinases/metabolismABSTRACT
Networks of coordinated alternative splicing (AS) events play critical roles in development and disease. However, a comprehensive knowledge of the factors that regulate these networks is lacking. We describe a high-throughput system for systematically linking trans-acting factors to endogenous RNA regulatory events. Using this system, we identify hundreds of factors associated with diverse regulatory layers that positively or negatively control AS events linked to cell fate. Remarkably, more than one-third of the regulators are transcription factors. Further analyses of the zinc finger protein Zfp871 and BTB/POZ domain transcription factor Nacc1, which regulate neural and stem cell AS programs, respectively, reveal roles in controlling the expression of specific splicing regulators. Surprisingly, these proteins also appear to regulate target AS programs via binding RNA. Our results thus uncover a large "missing cache" of splicing regulators among annotated transcription factors, some of which dually regulate AS through direct and indirect mechanisms.
Subject(s)
Alternative Splicing , Gene Regulatory Networks , Sequence Analysis, RNA/methods , Transcription Factors/metabolism , Animals , Cell Line , Embryonic Stem Cells/cytology , Embryonic Stem Cells/metabolism , HEK293 Cells , Humans , Mice , Neurons/cytology , Neurons/metabolism , RNA, Messenger/geneticsABSTRACT
Development is generally regarded as a unidirectional process that results in the acquisition of specialized cell fates. During this process, cellular identity is precisely defined by signaling cues that tailor the chromatin landscape for cell-specific gene expression programs. Once established, these pathways and cell states are typically resistant to disruption. However, loss of cell identity occurs during tumor initiation and upon injury response. Moreover, terminally differentiated cells can be experimentally provoked to become pluripotent. Chromatin reorganization is key to the establishment of new gene expression signatures and thus new cell identity. Here, we explore an emerging concept that lysine acetyltransferase (KAT) enzymes drive cellular plasticity in the context of somatic cell reprogramming and tumorigenesis.
Subject(s)
Cell Differentiation , Chromatin/metabolism , Gene Expression Regulation , Neoplasms/physiopathology , Animals , Carcinogenesis , Cell Proliferation , Humans , Lysine Acetyltransferases/metabolismABSTRACT
Cilia are hair-like cellular protrusions important in many aspects of eukaryotic biology. For instance, motile cilia enable fluid movement over epithelial surfaces, while primary (sensory) cilia play roles in cellular signalling. The molecular events underlying cilia dynamics, and particularly their disassembly, are not well understood. Phosphatase and tensin homologue (PTEN) is an extensively studied tumour suppressor, thought to primarily act by antagonizing PI3-kinase signalling. Here we demonstrate that PTEN plays an important role in multicilia formation and cilia disassembly by controlling the phosphorylation of Dishevelled (DVL), another ciliogenesis regulator. DVL is a central component of WNT signalling that plays a role during convergent extension movements, which we show here are also regulated by PTEN. Our studies identify a novel protein substrate for PTEN that couples PTEN to regulation of cilia dynamics and WNT signalling, thus advancing our understanding of potential underlying molecular etiologies of PTEN-related pathologies.
Subject(s)
Adaptor Proteins, Signal Transducing/metabolism , Cilia/metabolism , Epithelial Cells/metabolism , PTEN Phosphohydrolase/metabolism , Phosphoproteins/metabolism , Animals , Cell Line , Dishevelled Proteins , Embryo, Nonmammalian , Humans , Immunoblotting , Immunoprecipitation , Mice , Microscopy, Confocal , Phosphatidylinositol 3-Kinases , Phosphorylation , Retina/cytology , Wnt Signaling Pathway , Xenopus Proteins , Xenopus laevisABSTRACT
Embryonic stem cells are maintained in a self-renewing and pluripotent state by multiple regulatory pathways. Pluripotent-specific transcriptional networks are sequentially reactivated as somatic cells reprogram to achieve pluripotency. How epigenetic regulators modulate this process and contribute to somatic cell reprogramming is not clear. Here we performed a functional RNAi screen to identify the earliest epigenetic regulators required for reprogramming. We identified components of the SAGA histone acetyltransferase complex, in particular Gcn5, as critical regulators of reprogramming initiation. Furthermore, we showed in mouse pluripotent stem cells that Gcn5 strongly associates with Myc and that, upon initiation of somatic reprogramming, Gcn5 and Myc form a positive feed-forward loop that activates a distinct alternative splicing network and the early acquisition of pluripotency-associated splicing events. These studies expose a Myc-SAGA pathway that drives expression of an essential alternative splicing regulatory network during somatic cell reprogramming.
Subject(s)
Alternative Splicing , Cellular Reprogramming/genetics , Epigenomics , Histone Acetyltransferases/metabolism , Proto-Oncogene Proteins c-myc/genetics , Proto-Oncogene Proteins c-myc/metabolism , Animals , Cell Differentiation , Cell Movement/genetics , Cells, Cultured , Embryonic Stem Cells , Gene Expression Regulation, Developmental , Histone Acetyltransferases/genetics , Mice , Pluripotent Stem Cells , RNA Interference , RNA Processing, Post-Transcriptional/geneticsABSTRACT
Two studies by Sakurai et al. (2014) and Hu et al. (2014) in this issue of Cell Stem Cell add a new level of understanding to the mesenchymal-to-epithelial transition taking place during reprogramming, showing how this morphological transformation is promoted by Tet enzymes and blocked by kinase-dependent cytoskeletal organization.
Subject(s)
Cell Differentiation , Cellular Reprogramming/genetics , Cytoskeleton/metabolism , DNA Glycosylases/physiology , DNA Methylation , DNA-Binding Proteins/physiology , Embryonic Stem Cells/cytology , Epithelial-Mesenchymal Transition , Induced Pluripotent Stem Cells/cytology , Protein Serine-Threonine Kinases/genetics , Proto-Oncogene Proteins/physiology , Animals , Dioxygenases , HumansABSTRACT
The yeast Cyc8 (also known as Ssn6)-Tup1 complex regulates gene expression through a variety of mechanisms, including positioning of nucleosomes over promoters of some target genes to limit accessibility to the transcription machinery. To further define the functions of Cyc8-Tup1 in gene regulation and chromatin remodeling, we performed genome-wide profiling of changes in nucleosome organization and gene expression that occur upon loss of CYC8 or TUP1 and observed extensive nucleosome alterations in both promoters and gene bodies of derepressed genes. Our improved nucleosome profiling and analysis approaches revealed low-occupancy promoter nucleosomes (P nucleosomes) at locations previously defined as nucleosome-free regions. In the absence of CYC8 or TUP1, this P nucleosome is frequently lost, whereas nucleosomes are gained at -1 and +1 positions, accompanying up-regulation of downstream genes. Our analysis of public ChIP-seq data revealed that Cyc8 and Tup1 preferentially bind TATA-containing promoters, which are also enriched in genes derepressed upon loss of CYC8 or TUP1. These results suggest that stabilization of the P nucleosome on TATA-containing promoters may be a central feature of the repressive chromatin architecture created by the Cyc8-Tup1 corepressor, and that releasing the P nucleosome contributes to gene activation.
Subject(s)
Nuclear Proteins/metabolism , Nucleosomes/metabolism , Promoter Regions, Genetic , Repressor Proteins/metabolism , Yeasts/genetics , Yeasts/metabolism , Base Sequence , Cluster Analysis , Gene Expression Profiling , Gene Expression Regulation, Fungal , Genome, Fungal , Protein Binding , TATA Box , Transcription, GeneticABSTRACT
Reprogramming of somatic cells to a pluripotent state via expression of Oct4, Klf4, Myc, and Sox2 is a multistep process involving phased changes in gene expression. Here, we focus on the later stages of reprogramming, termed maturation and stabilization. We show that the stabilization phase and the acquisition of pluripotency are dependent on the removal of transgene expression late in the maturation phase. Clonal analysis of cells undergoing reprogramming revealed subsets of stabilization-competent (SC) and stabilization-incompetent (SI) cells. SC clones acquire a competency gene-expression signature late in the maturation phase. Functional analysis of SC signature genes identified enhancers of the transition to the stabilization phase and a distinct subset of genes required for the maintenance of pluripotency. Thus, the acquisition and maintenance of pluripotency are regulated by distinct molecular networks, and a specific regulatory program not previously implicated in reprogramming is required for the transition to transgene independence.
Subject(s)
Cellular Reprogramming/genetics , Pluripotent Stem Cells/cytology , Pluripotent Stem Cells/metabolism , Transcription Factors/metabolism , Animals , Cell Differentiation/genetics , Clone Cells , Embryo, Mammalian/cytology , Fibroblasts/cytology , Fibroblasts/metabolism , Gene Expression Profiling , Gene Expression Regulation, Developmental , Gene Regulatory Networks/genetics , Kruppel-Like Factor 4 , Mice , RNA, Messenger/genetics , RNA, Messenger/metabolism , Transcriptome/genetics , Transgenes/geneticsABSTRACT
Herein we present a protocol of reprogramming human adult fibroblasts into human induced pluripotent stem cells (hiPSC) using retroviral vectors encoding Oct3/4, Sox2, Klf4 and c-myc (OSKM) in the presence of sodium butyrate (1-3). We used this method to reprogram late passage (>p10) human adult fibroblasts derived from Friedreich's ataxia patient (GM03665, Coriell Repository). The reprogramming approach includes highly efficient transduction protocol using repetitive centrifugation of fibroblasts in the presence of virus-containing media. The reprogrammed hiPSC colonies were identified using live immunostaining for Tra-1-81, a surface marker of pluripotent cells, separated from non-reprogrammed fibroblasts and manually passaged (4,5). These hiPSC were then transferred to Matrigel plates and grown in feeder-free conditions, directly from the reprogramming plate. Starting from the first passage, hiPSC colonies demonstrate characteristic hES-like morphology. Using this protocol more than 70% of selected colonies can be successfully expanded and established into cell lines. The established hiPSC lines displayed characteristic pluripotency markers including surface markers TRA-1-60 and SSEA-4, as well as nuclear markers Oct3/4, Sox2 and Nanog. The protocol presented here has been established and tested using adult fibroblasts obtained from Friedreich's ataxia patients and control individuals( 6), human newborn fibroblasts, as well as human keratinocytes.
Subject(s)
Cytological Techniques/methods , Fibroblasts/cytology , Induced Pluripotent Stem Cells/cytology , Adult , Cell Dedifferentiation/physiology , Cellular Reprogramming/physiology , Humans , Infant, Newborn , Kruppel-Like Factor 4 , Transduction, GeneticABSTRACT
Posttranslational modifications of histone proteins play important roles in the modulation of gene expression. The Saccharomyces cerevisiae (yeast) 2-MDa SAGA (Spt-Ada-Gcn5) complex, a well-studied multisubunit histone modifier, regulates gene expression through Gcn5-mediated histone acetylation and Ubp8-mediated histone deubiquitination. Using a proteomics approach, we determined that the SAGA complex also deubiquitinates nonhistone proteins, including Snf1, an AMP-activated kinase. Ubp8-mediated deubiquitination of Snf1 affects the stability and phosphorylation state of Snf1, thereby affecting Snf1 kinase activity. Others have reported that Gal83 is phosphorylated by Snf1, and we found that deletion of UBP8 causes decreased phosphorylation of Gal83, which is consistent with the effects of Ubp8 loss on Snf1 kinase functions. Overall, our data indicate that SAGA modulates the posttranslational modifications of Snf1 in order to fine-tune gene expression levels.
Subject(s)
Endopeptidases/metabolism , Histones/genetics , Protein Serine-Threonine Kinases/metabolism , Saccharomyces cerevisiae Proteins/metabolism , Saccharomyces cerevisiae/metabolism , Trans-Activators/metabolism , AMP-Activated Protein Kinases , Acetylation , Endopeptidases/genetics , Gene Expression Regulation, Fungal , Histone Acetyltransferases/metabolism , Histones/biosynthesis , Histones/metabolism , Phosphorylation , Plasmids , Protein Processing, Post-Translational , Proteomics , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae Proteins/genetics , UbiquitinationABSTRACT
Histone deacetylase inhibitors (HDACIs) are promising anti-tumor agents that selectively induce cell cycle arrest, differentiation and/or apoptosis of tumor cells. Fundamentally, HDACIs are proposed to function by activating the transcription of genes, including the potent cyclin dependent kinase inhibitor p21(WAF1). However, HDACIs primarily increase p21(WAF1) expression at the post-transcriptional level in HepG2 cells, implying that these anti-tumor agents regulate genes at multiple levels. Here, two novel cis-acting elements in the 3' untranslated region (UTR) of p21(WAF1) are identified that control the ability of HDACIs to induce p21(WAF1) mRNA stabilization. Collectively, these studies highlight the complexity of HDACIs in gene regulation.
Subject(s)
3' Untranslated Regions/drug effects , Antineoplastic Agents/pharmacology , Cyclin-Dependent Kinase Inhibitor p21/genetics , Gene Expression Regulation/drug effects , Histone Deacetylase Inhibitors/pharmacology , Regulatory Elements, Transcriptional/drug effects , 3' Untranslated Regions/genetics , Animals , Base Sequence , Cell Line, Tumor , Humans , Mice , Molecular Sequence Data , RNA Stability , Regulatory Elements, Transcriptional/genetics , Transcription, GeneticABSTRACT
The SAGA complex provides a paradigm for multisubunit histone modifying complexes. Although first characterized as a histone acetyltransferase, because of the Gcn5 subunit, SAGA is now known to contain a second activity, a histone deubiquitinase, as well as subunits important for interactions with transcriptional activators and the general transcription machinery. The functions of SAGA in transcriptional activation are well-established in Saccharomyces cerevisiae. Recent studies in S. pombe, Drosophila, and mammalian systems reveal that SAGA also has important roles in transcript elongation, the regulation of protein stability, and telomere maintenance. These functions are essential for normal embryo development in flies and mice, and mutations or altered expression of SAGA subunits correlate with neurological disease and aggressive cancers in humans.
Subject(s)
Multiprotein Complexes/metabolism , Trans-Activators/metabolism , Animals , Embryonic Development , Histone Acetyltransferases/metabolism , Humans , Neoplasms/metabolism , UbiquitinationABSTRACT
Decitabine is a potent demethylating agent that exhibits clinical activity against myeloid malignancies. Numerous genes silenced by hypermethylation are reactivated by decitabine through a mechanism involving promoter demethylation with subsequent release of histone deacetylases (HDACs) and accumulation of acetylated histones. Recent studies indicating that decitabine also induces regional chromatin remodeling of some unmethylated genes suggest additional mechanisms of action. Decitabine reactivates unmethylated p21WAF1 in some AML cell lines but the possible occurrence of p21WAF1 methylation in AML in vivo has not been studied in detail and decitabine effects on p21WAF1 chromatin remodeling have not been reported. We found that p21WAF1 mRNA was undetectable in 6 of 24 AML patient samples and 4 of 5 AML cell lines but there was no evidence of p21WAF1 promoter methylation. However, decitabine induced p21WAF1 in AML cell lines KG-1 and KG-1a in association with release of HDAC1 and increased acetylated histone H3 at the unmethylated p21WAF1 promoter. Decitabine effects on p21WAF1 histone acetylation and induction were enhanced by the HDAC inhibitor trichostatin A and were independent of wild type p53. Our findings indicate that decitabine can relieve p21WAF1 repression in AML by a mechanism that involves release of HDAC1 without requiring promoter demethylation. Furthermore, our study provides evidence that combined decitabine and HDAC inhibitor treatment can enhance chromatin remodeling and reactivation of an unmethylated tumor suppressor gene. This latter finding is of relevance to the clinical use of these agents in AML as we found the p21WAF1 promoter to be unmethylated in vivo.
Subject(s)
Azacitidine/analogs & derivatives , Cyclin-Dependent Kinase Inhibitor p21/metabolism , DNA Methylation , Enzyme Inhibitors/pharmacology , Histone Deacetylases/metabolism , Leukemia, Myeloid, Acute/mortality , Neoplasm Proteins/metabolism , Promoter Regions, Genetic , Acylation/drug effects , Azacitidine/pharmacology , Azacitidine/therapeutic use , Chromatin Assembly and Disassembly/drug effects , DNA Methylation/drug effects , Decitabine , Enzyme Inhibitors/therapeutic use , Histone Deacetylase 1 , Histone Deacetylase Inhibitors , Histones/metabolism , Humans , Hydroxamic Acids/pharmacology , K562 Cells , Leukemia, Myeloid, Acute/drug therapy , Neoplasm Proteins/antagonists & inhibitors , Promoter Regions, Genetic/drug effects , Protein Processing, Post-Translational/drug effects , Tumor Suppressor Protein p53/metabolismABSTRACT
Histone deacetylase inhibitors (HDIs) induce cell cycle arrest, differentiation and/or apoptosis in numerous cancer cell types and have shown promise in clinical trials. These agents are particularly novel, given their ability to selectively influence gene expression. Previously, we demonstrated that the HDIs butyrate and trichostatin A (TSA) directly repress c-Src proto-oncogene expression in many cancer cell lines. Activation and/or overexpression of c-Src have been frequently observed in numerous malignancies, especially of the colon. Therefore, our observation was particularly interesting since butyrate is a naturally abundant component of the large intestine and has been suggested to be a cancer-preventive agent. However, c-Src is not the only Src family kinase (SFK) member to be implicated in the development of human cancers, including those of the colon. Therefore, the relative expression levels of known SFKs were examined in a panel of human colon cancer cell lines. We found a surprisingly diverse expression pattern but noted that most cell lines expressed relatively high levels of at least 2 SFKs. When the effects of butyrate and TSA were examined in representative cell lines, the expression of all SFKs was repressed in a dose- and time-dependent manner. Further, detailed examination of Lck, Yes and Lyn demonstrated that this repression had a direct effect on transcription and was independent of new protein synthesis. These results mirror our earlier data obtained with c-Src and suggest that SFKs are a major target of HDIs and likely account in part for the anticancer effects of these promising new drugs.
Subject(s)
Butyrates/pharmacology , Colonic Neoplasms/metabolism , Histone Deacetylase Inhibitors , Hydroxamic Acids/pharmacology , Transcription, Genetic/drug effects , src-Family Kinases/metabolism , Chloramphenicol O-Acetyltransferase/antagonists & inhibitors , Chloramphenicol O-Acetyltransferase/metabolism , Colonic Neoplasms/genetics , Dose-Response Relationship, Drug , Down-Regulation , Humans , Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/antagonists & inhibitors , Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/genetics , Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/metabolism , Oncogene Protein pp60(v-src)/antagonists & inhibitors , Oncogene Protein pp60(v-src)/genetics , Oncogene Protein pp60(v-src)/metabolism , Proto-Oncogene Mas , Proto-Oncogene Proteins c-yes/antagonists & inhibitors , Proto-Oncogene Proteins c-yes/genetics , Proto-Oncogene Proteins c-yes/metabolism , Time Factors , Tumor Cells, Cultured , src-Family Kinases/antagonists & inhibitors , src-Family Kinases/geneticsABSTRACT
Histone deacetylase inhibitors (HDIs) are thought to act primarily at the level of transcription inducing cell cycle arrest, differentiation and/or apoptosis in many cancer cell types. Induction of the potent cdk/cyclin inhibitor p21WAF1 is a key feature of this HDI mediated transcriptional re-programming phenomenon. However, in the current study we report that HDIs are also capable of inducing p21WAF1 through purely post-transcriptional events, namely increased mRNA stability. These studies highlight our growing appreciation for the complexities of HDI mediated effects and challenge our preconceptions regarding the action of these promising anti-neoplastics.